Gilead Sciences Inc
GILDHealthcare|Drug Manufacturers - General|USA
$140.13
+0.42 (+0.30%)
DCF (FCF)
$82.91
Earnings Power
$67.72
Financials
Financial Snapshot
Market Cap
$173.93B
Enterprise Value
$-15.24B
Revenue (TTM)
$29.44B
Net Income (TTM)
$8.51B
Cash & Equivalents
$9.62B
Net Cash/Share
$-21.53
Free Cash Flow (TTM)
$9.46B
Operating CF (TTM)
$10.02B
Debt/Equity
1.1
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $11.89B | $25.51B | $30.09B | $24.35B | $7.41B | $6.52B | $6.38B | $7.26B | $11.57B | $9.61B | $9.61B | |
| Operating Cash Flow | $17.05B | $11.90B | $8.40B | $9.14B | $8.17B | $11.38B | $9.07B | $8.01B | $10.83B | $10.02B | $10.02B | |
| Free Cash Flow | $16.30B | $11.31B | $7.48B | $8.32B | $7.52B | $10.80B | $8.34B | $7.42B | $10.30B | $9.46B | $9.46B | |
| Capital Expenditure | $-748.0M | $-590.0M | $-924.0M | $-825.0M | $-650.0M | $-579.0M | $-728.0M | $-585.0M | $-523.0M | $-563.0M | $-563.0M | |
| Financing Cash Flow | $-9.72B | $3.39B | $-12.32B | $-7.63B | $770.0M | $-8.88B | $-6.47B | $-5.13B | $-3.43B | $-7.75B | $-7.75B |
R&D Spending
R&D (TTM)
$5.80B
R&D Intensity
19.7%
R&D Growth YoY
+0.0%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.39B | $26.11B | $22.13B | $22.45B | $24.69B | $27.30B | $27.28B | $27.12B | $28.75B | $29.44B | $29.44B | |
| R&D Expense | $5.10B | $3.73B | $3.92B | $4.05B | $5.04B | $4.60B | $4.98B | $5.72B | $5.91B | $5.80B | $5.80B | |
| R&D % of Revenue | 16.8% | 14.3% | 17.7% | 18.1% | 20.4% | 16.9% | 18.2% | 21.1% | 20.5% | 19.7% | 19.7% | |
| SG&A | $3.40B | $3.88B | $4.06B | $4.38B | $5.15B | $5.25B | $5.67B | $6.06B | $6.00B | $5.71B | $5.71B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.39B | $26.11B | $22.13B | $22.45B | $24.69B | $27.30B | $27.28B | $27.12B | $28.75B | $29.44B | $29.44B | |
| Cost of Goods Sold | $4.26B | $4.37B | $4.85B | $4.67B | $4.57B | $6.60B | $5.66B | $6.50B | $6.25B | $6.23B | $6.23B | |
| Gross Profit | $26.13B | $21.74B | $17.27B | $17.77B | $20.12B | $20.70B | $21.62B | $20.62B | $22.50B | $23.21B | $23.21B | |
| R&D | $5.10B | $3.73B | $3.92B | $4.05B | $5.04B | $4.60B | $4.98B | $5.72B | $5.91B | $5.80B | $5.80B | |
| SG&A | $3.40B | $3.88B | $4.06B | $4.38B | $5.15B | $5.25B | $5.67B | $6.06B | $6.00B | $5.71B | $5.71B | |
| Operating Income | $17.63B | $14.12B | $9.30B | $9.34B | $9.93B | $10.86B | $10.97B | $8.84B | $10.60B | $11.70B | $11.70B | |
| Interest Expense | $-964.0M | $-1.12B | $-1.08B | $-995.0M | $-984.0M | $-1.00B | $-935.0M | $-944.0M | $-977.0M | $-1.02B | $-1.02B | |
| Pretax Income | $17.10B | $13.53B | $7.80B | $5.16B | $1.67B | $8.28B | $5.81B | $6.86B | $690.0M | $9.80B | $9.80B | |
| Net Income | $13.50B | $4.63B | $5.46B | $5.39B | $123.0M | $6.22B | $4.59B | $5.67B | $480.0M | $8.51B | $8.51B | |
| EPS (Diluted) | 9.94 | 3.51 | 4.17 | 4.22 | 0.10 | 4.93 | 3.64 | 4.50 | 0.38 | 6.78 | 6.77 | |
| EBITDA | $19.22B | $15.93B | $10.30B | $7.56B | $4.13B | $11.33B | $8.85B | $10.50B | $4.43B | $13.58B | $13.58B | |
| Shares Out. (M) | 1358.00 | 1319.00 | 1308.00 | 1277.00 | 1263.00 | 1262.00 | 1262.00 | 1258.00 | 1255.00 | 1255.00 | 1252.00 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.23B | $7.59B | $17.94B | $11.63B | $6.00B | $5.34B | $5.41B | $6.08B | $9.99B | $7.56B | $7.56B | |
| Marketable Securities | $3.67B | $17.92B | $12.15B | $12.72B | $1.41B | $1.18B | $973.0M | $1.18B | $1.58B | $2.05B | $2.05B | |
| Total Current Assets | $19.59B | $31.82B | $35.84B | $30.30B | $16.00B | $14.77B | $14.44B | $16.09B | $19.17B | $18.34B | $18.34B | |
| Total Assets | $56.98B | $70.28B | $63.67B | $61.63B | $68.41B | $67.95B | $63.17B | $62.13B | $58.99B | $59.02B | $59.02B | |
| Total Current Liabilities | $9.22B | $11.63B | $10.61B | $9.76B | $11.40B | $11.61B | $11.24B | $11.28B | $12.00B | $11.81B | $11.81B | |
| Long-Term Debt | $26.35B | $30.80B | $24.57B | $22.09B | $28.64B | $25.18B | $22.96B | $23.19B | $24.90B | $22.13B | $22.13B | |
| Total Liabilities | $37.61B | $49.78B | $42.14B | $38.98B | $50.19B | $46.89B | $41.96B | $39.38B | $39.75B | $36.41B | $36.41B | |
| Stockholders' Equity | $18.89B | $20.44B | $21.39B | $22.52B | $18.20B | $21.07B | $21.24B | $22.83B | $19.33B | $22.70B | $22.70B | |
| Retained Earnings | $18.15B | $19.01B | $19.02B | $19.39B | $14.38B | $16.32B | $15.69B | $16.30B | $11.50B | $13.73B | $13.73B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $17.05B | $11.90B | $8.40B | $9.14B | $8.17B | $11.38B | $9.07B | $8.01B | $10.83B | $10.02B | $10.02B | |
| Capital Expenditure | $-748.0M | $-590.0M | $-924.0M | $-825.0M | $-650.0M | $-579.0M | $-728.0M | $-585.0M | $-523.0M | $-563.0M | $-563.0M | |
| Free Cash Flow | $16.30B | $11.31B | $7.48B | $8.32B | $7.52B | $10.80B | $8.34B | $7.42B | $10.30B | $9.46B | $9.46B | |
| Investing Cash Flow | $-11.98B | $-16.07B | $14.36B | $-7.82B | $-14.62B | $-3.13B | $-2.47B | $-2.27B | $-3.45B | $-4.79B | $-4.79B | |
| Financing Cash Flow | $-9.72B | $3.39B | $-12.32B | $-7.63B | $770.0M | $-8.88B | $-6.47B | $-5.13B | $-3.43B | $-7.75B | $-7.75B | |
| Issuance of Stock | $208.0M | $234.0M | $289.0M | $209.0M | $256.0M | $169.0M | $309.0M | $232.0M | $422.0M | $408.0M | $408.0M | |
| Repurchase of Stock | $-11.00B | $-954.0M | $-2.90B | $-1.75B | $-1.58B | $-546.0M | $-1.40B | $-1.00B | $-1.15B | $-1.92B | $-1.92B | |
| Issuance of Debt | $6.25B | $8.98B | $0.00 | $0.00 | $8.18B | $0.00 | $0.00 | $1.98B | $3.46B | $0.00 | $0.00 | |
| Payments of Debt | $-1.98B | $-1.81B | $-6.25B | $-2.75B | $-2.50B | $-4.75B | $-1.50B | $-2.25B | $-1.97B | $-1.79B | $-1.79B | |
| Stock Based Comp. | $380.0M | $638.0M | $845.0M | $636.0M | $643.0M | $635.0M | $637.0M | $766.0M | $835.0M | $894.0M | $894.0M | |
| Net Change in Cash | $-4.62B | $-641.0M | $10.35B | $-6.31B | $-5.63B | $-659.0M | $74.0M | $673.0M | $3.91B | $-2.43B | $-2.43B |
Dilution Tracker
Shares Outstanding
1252M
5-Year Share Growth
-0.8%
Stock Issuance (TTM)
$408.0M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1358.00 | 1319.00 | 1308.00 | 1277.00 | 1263.00 | 1262.00 | 1262.00 | 1258.00 | 1255.00 | 1255.00 | 1252.00 | |
| YoY Change % | — | -2.9% | -0.8% | -2.4% | -1.1% | -0.1% | 0.0% | -0.3% | -0.2% | 0.0% | -0.2% | |
| Stock Issuance | $208.0M | $234.0M | $289.0M | $209.0M | $256.0M | $169.0M | $309.0M | $232.0M | $422.0M | $408.0M | $408.0M | |
| Stock Repurchase | $-11.00B | $-954.0M | $-2.90B | $-1.75B | $-1.58B | $-546.0M | $-1.40B | $-1.00B | $-1.15B | $-1.92B | $-1.92B | |
| Stock Based Comp. | $380.0M | $638.0M | $845.0M | $636.0M | $643.0M | $635.0M | $637.0M | $766.0M | $835.0M | $894.0M | $894.0M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 86.0% | 83.3% | 78.1% | 79.2% | 81.5% | 75.8% | 79.3% | 76.0% | 78.3% | 78.8% | 78.8% | |
| Operating Margin % | 58.0% | 54.1% | 42.0% | 41.6% | 40.2% | 39.8% | 40.2% | 32.6% | 36.9% | 39.7% | 39.7% | |
| Net Margin % | 44.4% | 17.7% | 24.7% | 24.0% | 0.5% | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% | 28.9% | |
| EBITDA Margin % | 63.2% | 61.0% | 46.6% | 33.7% | 16.7% | 41.5% | 32.4% | 38.7% | 15.4% | 46.1% | 46.1% | |
| FCF Margin % | 53.6% | 43.3% | 33.8% | 37.1% | 30.5% | 39.6% | 30.6% | 27.4% | 35.8% | 32.1% | 32.1% | |
| ROE % | 72.2% | 23.5% | 26.1% | 24.5% | 0.6% | 31.7% | 21.7% | 25.7% | 2.3% | 40.5% | 41.5% | |
| ROA % | 24.8% | 7.3% | 8.1% | 8.6% | 0.2% | 9.1% | 7.0% | 9.0% | 0.8% | 14.4% | 14.7% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)20.70
Historical6.64 / 18.75 / 1072.94
Industry Med.20.96
P/S6.00
Historical2.68 / 3.69 / 6.61
Industry Med.2.30
P/B7.66
Historical3.45 / 4.52 / 10.26
Industry Med.2.03
EV/EBITDA13.93
Historical5.30 / 11.25 / 57.02
Industry Med.12.96
EV/Revenue6.43
Historical3.34 / 4.08 / 7.11
Industry Med.2.47
P/FCF18.64
Historical5.39 / 10.69 / 20.55
Industry Med.23.50
Intrinsic Value Models
DCF (FCF Based)
$82.91
Peter Lynch Value
$41.24
Median P/S Value
$86.58
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | 7.20 | 20.41 | 15.00 | 15.40 | 582.60 | 14.73 | 23.59 | 18.00 | 243.08 | 18.10 | 20.70 | |
| PS Ratio | 3.20 | 3.62 | 3.70 | 3.70 | 2.98 | 3.36 | 3.97 | 3.76 | 4.03 | 5.23 | 6.00 | |
| PB Ratio | 4.97 | 4.58 | 3.75 | 3.65 | 4.01 | 4.32 | 5.04 | 4.42 | 5.96 | 6.71 | 7.66 | |
| EV/EBITDA | 5.66 | 6.39 | 7.53 | 10.93 | 23.49 | 9.82 | 14.22 | 11.30 | 29.36 | 12.34 | 13.93 | |
| EV/Revenue | 3.58 | 3.90 | 3.51 | 3.68 | 3.93 | 4.07 | 4.61 | 4.37 | 4.53 | 5.69 | 6.43 |
Analyst Estimates & Quality
Altman Z-Score
4.42
Safe
Piotroski F-Score
8
Strong
Beneish M-Score
-2.36
Unlikely Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $30,209M | $32,010M | $33,697M |
| Net Income | $10,693M | $11,923M | $12,858M |
| EPS | 7.29 | 8.14 | 9.06 |
| Book Value per Share | 21.71 | 25.12 | 31.37 |
| Operating Cash Flow per Share | 9.07 | 9.68 | 10.89 |
| Operating CF | $11,349.38M | $12,113.10M | $13,630.15M |
Dividends
Dividend/Share (TTM)
$3.16
Dividend Yield
2.25%
Yield 10Y Median
3.48%
Frequency
Quarterly
Recent Payments
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-03-13 | 2026-03-30 | $0.82 | Cash Div. |
| 2025-12-15 | 2025-12-30 | $0.79 | Cash Div. |
| 2025-09-15 | 2025-09-29 | $0.79 | Cash Div. |
| 2025-06-13 | 2025-06-27 | $0.79 | Cash Div. |
| 2025-03-14 | 2025-03-28 | $0.79 | Cash Div. |
| 2024-12-13 | 2024-12-30 | $0.77 | Cash Div. |
| 2024-09-13 | 2024-09-27 | $0.77 | Cash Div. |
| 2024-06-14 | 2024-06-27 | $0.77 | Cash Div. |
| 2024-03-14 | 2024-03-28 | $0.77 | Cash Div. |
| 2023-12-14 | 2023-12-28 | $0.75 | Cash Div. |
| 2023-09-14 | 2023-09-28 | $0.75 | Cash Div. |
| 2023-06-14 | 2023-06-29 | $0.75 | Cash Div. |
| 2023-03-14 | 2023-03-30 | $0.75 | Cash Div. |
| 2022-12-14 | 2022-12-29 | $0.73 | Cash Div. |
| 2022-09-14 | 2022-09-29 | $0.73 | Cash Div. |
| 2022-06-14 | 2022-06-29 | $0.73 | Cash Div. |
| 2022-03-14 | 2022-03-30 | $0.73 | Cash Div. |
| 2021-12-14 | 2021-12-30 | $0.71 | Cash Div. |
| 2021-09-14 | 2021-09-29 | $0.71 | Cash Div. |
| 2021-06-14 | 2021-06-29 | $0.71 | Cash Div. |
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Biktarvy | $14.33B |
| AmBisome | $509.0M |
| Descovy | $2.76B |
| Genvoya | $1.50B |
| Odefsey | $1.17B |
| Other | $290.0M |
| Other Human immunodeficiency virus (HIV) | $500.0M |
| Other Liver Disease | $874.0M |
| Royalty, contract and other revenues | $527.0M |
| Sofosbuvir/Velpatasvir | $1.27B |
| Symtuza - Revenue share | $495.0M |
| Tecartus | $344.0M |
| Trodelvy | $1.40B |
| Veklury | $911.0M |
| Vemlidy | $1.07B |
| Yescarta | $1.50B |
By Geography
| Segment | 2025 |
|---|---|
| United States | $20.88B |
| Europe | $5.06B |
| Other International | $3.50B |